Recent Updates
Recently added Catalysts
LPCN Positive Sentiment Score: 70/100

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Thursday, May 9, 2024 1 min read
Key Takeaway: Lipocine Inc. has announced its financial results for Q1 2024, highlighting growth and ongoing developments in its product pipeline. The company is focusing on LPCN 1154 for postpartum treatment and has secured a distribution agreement for TLANDO® in the GCC. Additionally, Lipocine is preparing for a virtual event to discuss LPCN 2401's role in obesity management.
Price reaction · baseline $5.23 (2024-05-09T16:13:00.000Z) · hit during market hours · clean, no other LPCN news in the window
day 0 close · peak
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lipocine reported financial results indicating growth.
  • The company is actively pursuing new agreements and collaborations.
  • Positive results for LPCN 1154 and upcoming events show potential.

Full Press Release Details

• May 9, 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. LPCN 1154 for Postpartum

Recent

Press

• October 10, 2024

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

• October 8, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

• October 2, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Innovating beyond boundaries for patients

Frequently Asked Questions

What financial results did Lipocine announce?

Lipocine announced positive financial results for the first quarter of 2024.

What is LPCN 1154 used for?

LPCN 1154 is being developed for postpartum treatment.

What agreement did Lipocine secure recently?

Lipocine secured a supply and distribution agreement for TLANDO® in the GCC.

When is the virtual KOL event for LPCN 2401?

The virtual KOL event for LPCN 2401 is scheduled for October 16, 2024.

Tags: LPCN Viatris Investor Conferences Healthcare Lipocine financial results Q1 2024 biopharmaceutical
Last updated: May 9, 2024

Biotech snapshot

Cash runway
$25M liquidity · $1M/mo burn
~30 mo
Minimal dilution risk
Lead asset
testosterone undecanoate, LPCN 1021Phase 3
Male Hypogonadism →

Catalyst track record

+266%
best trade around LPCN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for LPCN.

See every catalyst's timing & PoA →